CATL Shares Fall as Hungary Plant Faces Safety Halt 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Rejects Apple Trade Secret Theft Claims 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
BOULDER, Colo., March 05, 2018 -- Biodesix, Inc., a molecular diagnostics company that develops and commercializes non-invasive, blood-based diagnostic tests for oncology, today announced that the Company increased the size of its offering of its series G preferred shares in a follow-on sale and entered into a debt refinancing agreement with Innovatus Capital Partners to provide a $23 million term loan.
|
|||||
Biodesix will use the additional capital for the continued development of new blood-based diagnostic tests for clinical use with immunotherapies, as well as the continued expansion of the company’s offering of its commercialized VeriStrat® and GeneStrat® tests.
“We are pleased to add a new lender to our distinguished investor group,” said David Brunel, chief executive officer of Biodesix. “Innovatus Capital Partners has significant expertise in healthcare and a strong record in the diagnostic space and we are proud to have their backing.”
“We are proud to support Biodesix in its pursuit of providing innovative diagnostic tests for patients with lung cancer,” said Claes Ekstrom, managing director of Innovatus. “We look forward to forging a long-term relationship with the outstanding team at Biodesix as they continue to develop and provide solutions to save patient lives.”
Brunel added, “We are also excited to have Scott Hutton join our team as chief operating officer. Scott is an accomplished and strategic transformational leader with over nineteen years of experience in the medical device/technology industry, and he’s a great addition to our team.”
Scott Hutton was most recently the senior vice president and general manager of Spectranetics. Prior to Spectranetics, he served as vice president and general manager of the Neurosurgery unit of Medtronic and held several other positions with the company during his tenure. Hutton first joined Medtronic in 2000.
Biodesix, VeriStrat and GeneStrat are trademarks or registered trademarks of Biodesix, Inc. All other trademarks referenced herein are property of their respective owners.
About Biodesix
Biodesix® is a molecular diagnostics company advancing the development of innovative, multi-omic blood-based tests in oncology to enable precision medicine. Biodesix discovers, develops and commercializes multivariate protein and genomic diagnostic blood tests, including the GeneStrat® and VeriStrat® tests, that deliver results within 72 hours. The company is changing the standard of care by providing physicians with diagnostic tests for better therapeutic guidance, more accurate prognosis and enhanced disease monitoring to improve patient outcomes. At the forefront of precision medicine, Biodesix is developing new blood tests to identify patients who may benefit from immunotherapies. In addition to developing novel diagnostics independently, the company partners with biotechnology and pharmaceutical companies to develop companion diagnostics for use with therapeutic agents.
About Innovatus Life Sciences Lending Fund
Innovatus Life Sciences Lending Fund, I LP (“the Fund”) is an affiliate of Innovatus Capital Partners, LLC, an independent adviser and portfolio management firm with ~$1.6 billion in assets under management. Innovatus has a dedicated team of life sciences investment professionals with deep experience in healthcare, including life sciences. The Fund is currently focused on providing debt financing to medical device, diagnostic and biotechnology companies that address unmet medical needs, improve patient outcomes and reduce overall healthcare expenditures. Innovatus Capital Partners, LLC adheres to an investment strategy that identifies distressed, disruptive and growth opportunities in the less obvious market segments across multiple asset categories with a unifying theme of capital preservation, income generation, and upside optionality. Further information can be found at innovatuscp.com.
Contact:
Rachel Biederman, Biodesix, Inc.
720-214-5774
[email protected]
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/680890c5-7429-4738-854e-2aafd74514d1
